Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

(2021) Jacob P. Laubach et al.   Blood Cancer Journal

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

(2021) Joseph Mikhael et al.   Blood Cancer Journal

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

(2021) Darrell White et al.   JOURNAL OF CLINICAL ONCOLOGY

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

(2021) Saad Z Usmani et al.   LANCET

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

(2021) Karun Neupane et al.   Journal of Blood Medicine

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

(2020) Deepu Madduri et al.   BLOOD

How I Manage CLL with Venetoclax-Based Treatments

(2020) William George Wierda et al.   BLOOD

A Phase 1 Study of Ruxolitinib, Lenalidomide and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

(2020) James R Berenson et al.   CLINICAL CANCER RESEARCH

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

(2020) Maria Gavriatopoulou et al.   LEUKEMIA

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

(2020) Nikhil C. Munshi et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

(2020) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

(2020) Cristina Gasparetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

(2020) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

(2020) Jacob P Laubach et al.   LANCET ONCOLOGY

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

(2019) Jonathan L. Kaufman et al.   Blood Cancer Journal

A Phase 1b/2 Study of Oprozomib in Patients With Advanced Multiple Myeloma and Waldenström Macroglobulinemia

(2019) Irene M. Ghobrial et al.   CLINICAL CANCER RESEARCH

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

(2019) Esperanza M Algarín et al.   HAEMATOLOGICA

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

(2019) Paul G Richardson et al.   LANCET ONCOLOGY

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

(2019) Jonathan L. Kaufman et al.   BLOOD

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

(2019) Nizar Bahlis et al.   BLOOD

A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

(2019) Shaji Kumar et al.   Clinical Lymphoma Myeloma & Leukemia

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

(2019) Chad C. Bjorklund et al.   LEUKEMIA

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

(2019) Hans C. Lee et al.   Blood Cancer Journal

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

(2019) Pedro Mogollón et al.   Cells

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

(2018) Paul G Richardson et al.   Future Oncology

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

(2018) Philippe Moreau et al.   LANCET ONCOLOGY

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

(2016) S. J. Harrison et al.   CLINICAL CANCER RESEARCH

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

(2016) Andrew J Yee et al.   LANCET ONCOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

(2016) Rakesh Popat et al.   Lancet Haematology

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

(2013) D. Chauhan et al.   CLINICAL CANCER RESEARCH

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

(2012) Jeffrey L. Wolf et al.   LEUKEMIA & LYMPHOMA

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Aminopeptidase N (CD13) as a target for cancer chemotherapy

(2010) Malin Wickström et al.   CANCER SCIENCE

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

(2009) E. M. Ocio et al.   HAEMATOLOGICA

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER